In the past 48 hours, the health care industry has seen key regulatory shifts, major deals, and persistent fraud concerns under the Trump administration's influence. CMS finalized a 2.48 percent Medicare Advantage payment increase for 2027, up from a proposed 0.09 percent after industry pushback, injecting about 13 billion dollars in additional plan payments.[1] This follows earlier flat-rate fears, marking a modest win for insurers compared to prior years' tighter margins.

Mergers and acquisitions surged amid pricing pressures. Biogen announced a 5.6 billion dollar acquisition of Apellis on March 30 to expand in immunology and nephrology, while Croma-Pharma reacquired Synocrom for knee osteoarthritis treatment, reentering orthopedics.[6][8] Merit Medical Systems also bought View, fueling a robust M&A wave despite disruptions.[7]

Regulatory moves include a new CMS pilot allowing hemp and CBD products in select models like ACO REACH, starting April 1.[1] Abbvie and Genentech joined TrumpRx, the tenth and eleventh firms offering discounted drugs via the White House site.[1] A UK-US pharma deal promises zero tariffs on UK exports worth 5 billion pounds annually but raises NHS costs by 25 percent for branded medicines.[2]

Fraud alarms rang with CBS exposing California hospice doctor Rajiv Bhuva linked to 71.7 million dollars in 2024 Medicare claims across 126 providers, highlighting ongoing vulnerabilities.[3][11] Meanwhile, ARPA-H unveiled three potential osteoarthritis treatments after investing tens of millions, with patient trials imminent.[1]

Leaders respond proactively: Southern Nevada Health District expanded naloxone distribution to 200,000 doses and launched street medicine for the homeless.[4] New York faces pushback on Gov. Hochul's Medicaid biomarker testing restrictions, potentially reversing 2023 gains.[5]

Compared to last week's quieter news, this period shows accelerated Trump-era policies boosting payments and innovation but straining budgets and fraud risks. No major consumer shifts or supply chain breaks reported, though global partnerships like EP BrainHealth emphasize brain research.[12] Overall, industry leaders adapt via deals and pilots to navigate rising costs. (348 words)

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI